Cai J, Zhang X, Ji Y, Zhang P, She Z, Li H. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020;126(5):679–704.
Article
PubMed
CAS
Google Scholar
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey R, Deaton C, Cuisset T, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.
Article
PubMed
Google Scholar
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.
Article
PubMed
PubMed Central
Google Scholar
Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour J, Schattenberg J, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.
Article
PubMed
Google Scholar
Zhang XL, Fan JG, Wei L, Shi JP, Zheng MH. Promoting the term MAFLD: China in action. Lancet Gastroenterol Hepatol. 2022;7(7):598.
Article
PubMed
Google Scholar
Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M, Harrison S, Brunt E, Sanyal A. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–57.
Article
PubMed
Google Scholar
Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1991.
Article
PubMed
CAS
Google Scholar
Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, Hashim A, Kamal E, Mehrez M, Attia D. The NAFLD-MAFLD debate: Eminence vs evidence. Liver International. 2021;41(2):255–60.
Article
PubMed
Google Scholar
Wang T, George J, Zheng M. Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. Hepatobiliary Surg Nutr. 2021;10(6):849–52.
Article
PubMed
PubMed Central
Google Scholar
van Kleef L, de Knegt R. The transition from NAFLD to MAFLD: one size still does not fit all—time for a tailored approach? Hepatology. 2022. https://doi.org/10.1002/hep.32552.
Article
PubMed
Google Scholar
Younossi Z, Rinella M, Sanyal A, Harrison S, Brunt E, Goodman Z, Cohen D, Loomba R. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–8.
Article
PubMed
Google Scholar
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).[J] .Dig Liver Dis, 2022,;54:170–182. PMID: 34924319.
Duell P, Welty F, Miller M, Chait A, Hammond G, Ahmad Z, Cohen D, Horton J, Pressman G, Toth P. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the american heart association. Arter Thromb Vasc Biol. 2022. https://doi.org/10.1161/ATV0000000000000153.
Article
CAS
Google Scholar
Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138-2147.e2110.
Article
PubMed
Google Scholar
Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism. 2021. https://doi.org/10.1016/j.metabol.2020.154433.
Article
PubMed
CAS
Google Scholar
Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74(4):989–91.
Article
PubMed
Google Scholar
Zhang H, Wang Y, Chen C, Lu Y, Wang N. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J. 2021;134(13):1593–601.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kim H, Lee C, Ahn S, Lee K, Lee B, Baik S, Kim S, Lee J. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022. https://doi.org/10.1007/s10620-022-07508-6.
Article
PubMed
CAS
Google Scholar
Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y. Predicting coronary heart disease using risk factor categories for a japanese urban population, and comparison with the Framingham risk score: the suita study. J Atheroscler Thromb. 2016;23(9):1138–9.
Article
PubMed
Google Scholar
Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–28.
Article
PubMed
CAS
Google Scholar
Liu S, Wang J, Wu S, Niu J, Zheng R, Bie L, Xin Z, Wang S, Lin H, Zhao Z, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021. https://doi.org/10.1016/j.metabol.2021.154779.
Article
PubMed
CAS
Google Scholar
Liu H, Cao Y, Jin J, Guo Y, Zhu C, Wu N, Gao Y, Xu R, Dong Q, Zheng M, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hep Int. 2021;15(6):1337–46.
Article
Google Scholar
Noda T, Kamiya K, Hamazaki N, Nozaki K, Ichikawa T, Yamashita M, Uchida S, Maekawa E, Terada T, Reed J, et al. The prevalence of metabolic dysfunction-associated fatty liver disease and its association with physical function and prognosis in patients with acute coronary syndrome. J Clin Med. 2022. https://doi.org/10.3390/jcm11071847.
Article
PubMed
PubMed Central
Google Scholar
Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality a meta-analysis and systematic review of 12 620 736 individuals. Endocr Pract. 2022;28(7):667–72.
Article
PubMed
Google Scholar
Alexander M, Loomis A, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367: l5367.
Article
PubMed
PubMed Central
Google Scholar
Wu M, Zha M, Lv Q, Xie Y, Yuan K, Zhang X, Liu X. Non-alcoholic fatty liver disease and stroke: a Mendelian randomization study. Eur J Neurol. 2022;29(5):1534–7.
Article
PubMed
Google Scholar
George J, Gish RG, Geier A. MAFLD and cardiovascular events: what does the evidence show? Clin Gastroenterol Hepatol. 2021;19(10):2025–8.
Article
PubMed
Google Scholar
Niriella M, Ediriweera D, Kasturiratne A, De Silva S, Dassanayaka A, De Silva A, Kato N, Pathmeswaran A, Wickramasinghe A, de Silva H. Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study. PLoS ONE. 2021;16(2): e0245762.
Article
PubMed
PubMed Central
CAS
Google Scholar
Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172-2181.e2176.
Article
PubMed
Google Scholar
Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284–91.
Article
PubMed
CAS
Google Scholar
Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–9.
Article
PubMed
Google Scholar
Mantovani A, Csermely A, Tilg H, Byrne C, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-328224.
Article
PubMed
Google Scholar
Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism. 2021. https://doi.org/10.1016/j.metabol.2021.154868.
Article
PubMed
CAS
Google Scholar
Zhang Y, Lyu Z, Ma B, Li L, Wang W, Sheng C, Dai H, Huang Y, Song F, Song F, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hep Intl. 2022;16(4):835–45.
Article
Google Scholar
Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr DiabRep. 2021;21(5):15.
Google Scholar
Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–9.
Article
PubMed
Google Scholar
Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, et al. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol. 2019;4(10):794–804.
Article
PubMed
PubMed Central
Google Scholar
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.
Article
PubMed
Google Scholar
Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13.
Article
PubMed
Google Scholar
Han E, Lee Y, Kim Y, Kim B, Park J, Kim D, Ahn S, Lee B, Kang E, Cha B, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol. 2020;115(4):584–95.
Article
PubMed
Google Scholar
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.
Article
PubMed
Google Scholar
Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radical Biol Med. 2020;152:116–41.
Article
CAS
Google Scholar
Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1–19.
Article
PubMed
CAS
Google Scholar
Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22084156.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pasterkamp G. Methods of accelerated atherosclerosis in diabetic patients. Heart. 2013;99(10):743–9.
Article
PubMed
CAS
Google Scholar
Stahl E, Dhindsa D, Lee S, Sandesara P, Chalasani N, Sperling L. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art review. J Am Coll Cardiol. 2019;73(8):948–63.
Article
PubMed
Google Scholar
Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-Results from NHANES III. Front Med. 2021;8: 693507.
Article
Google Scholar
Ampuero J, Aller R, Gallego-Durán R, Banales J, Crespo J, García-Monzón C, Pareja M, Vilar-Gómez E, Caballería J, Escudero-García D, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48:1260–70.
Article
PubMed
CAS
Google Scholar
Koo BK, Allison MA, Criqui MH, Denenberg JO, Wright CM. The association between liver fat and systemic calcified atherosclerosis. J Vasc Surg. 2020;71(1):204-211.e204.
Article
PubMed
Google Scholar
Moon J, Kim W, Koo B, Cho N. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease. Gut and liver. 2022;16(3):433–42.
Article
PubMed
CAS
Google Scholar
Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the indian national association for the study of the liver, endocrine society of india, indian college of cardiology and indian society of gastroenterology. J Clin Exp Hepatol. 2015;5(1):51–68.
Article
PubMed
PubMed Central
Google Scholar
Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, Kobayashi T, Nogami A, Higurashi T, Kato S, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–32.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zeb I, Li D, Budoff M, Katz R, Lloyd-Jones D, Agatston A, Blumenthal R, Blaha M, Blankstein R, Carr J, et al. Nonalcoholic fatty liver disease and incident cardiac events: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2016;67(16):1965–6.
Article
PubMed
Google Scholar
Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol. 2020;18(10):2324-2331.e2324.
Article
PubMed
Google Scholar
Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep. 2019;9(1):11124.
Article
PubMed
PubMed Central
Google Scholar
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.
Article
PubMed
Google Scholar
Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6:33386.
Article
PubMed
PubMed Central
CAS
Google Scholar
Simon T, Roelstraete B, Khalili H, Hagström H, Ludvigsson J. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375–82.
Article
PubMed
Google Scholar
Xun Z, Zhao H. Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease? Hepatology. 2022. https://doi.org/10.1002/hep.32606.
Article
PubMed
Google Scholar
Glen J, Floros L, Day C, Pryke R. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ. 2016;354: i4428.
Article
PubMed
Google Scholar
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528–62.
Article
PubMed
Google Scholar
Younossi Z, Corey K, Lim J. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2021;160(3):912–8.
Article
PubMed
Google Scholar
Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, et al. The Asian Pacific Association for the study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hep Intl. 2020;14(6):889–919.
Article
Google Scholar
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596–646.
PubMed
PubMed Central
Google Scholar
Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis. Dig Dis Sci. 2016;61(7):2108–17.
Article
PubMed
PubMed Central
Google Scholar
Wong VW, Wong GL, Yeung JC, Fung CY, Chan JK, Chang ZH, Kwan CT, Lam HW, Limquiaco J, Chim AM, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology. 2016;63(3):754–63.
Article
PubMed
Google Scholar
Mantovani A, Csermely A, Petracca G, Beatrice G, Corey K, Simon T, Byrne C, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13.
Article
PubMed
Google Scholar
Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol. 2021;36(10):2960–6.
Article
PubMed
CAS
Google Scholar
Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease. BMJ. 2021;372: m4747.
Article
PubMed
Google Scholar
Targher G, Byrne C, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–705.
Article
PubMed
CAS
Google Scholar
Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N, Rein M, Serfaty D, Kenigsbuch S, Zelicha H, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019;71(2):379–88.
Article
PubMed
Google Scholar
Yaskolka Meir A, Rinott E, Tsaban G, Zelicha H, Kaplan A, Rosen P, Shelef I, Youngster I, Shalev A, Blüher M, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. 2021;70(11):2085–95.
Article
PubMed
Google Scholar
Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A, Ortiz-Morales AM, Gonzalez-Requero AI, Perez-Caballero AI, Yubero-Serrano EM, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399(10338):1876–85.
Article
PubMed
CAS
Google Scholar
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.
Article
PubMed
Google Scholar
Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C. Exercise-based Interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression. Clin Gastroenterol Hepatol. 2016;14(10):1398–411.
Article
PubMed
Google Scholar
Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann Smith C, Wilkins E, Rayner M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc. 2016. https://doi.org/10.1161/JAHA.115.002495.
Article
PubMed
PubMed Central
Google Scholar
Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124(7):789–95.
Article
PubMed
PubMed Central
Google Scholar
Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease. Am J Respir Crit Care Med. 2019;199(7):830–41.
Article
PubMed
PubMed Central
CAS
Google Scholar
Covassin N, Singh P, McCrady-Spitzer SK, St Louis EK, Calvin AD, Levine JA, Somers VK. Effects of experimental sleep restriction on energy intake, energy expenditure, and visceral obesity. J Am Coll Cardiol. 2022;79(13):1254–65.
Article
PubMed
Google Scholar
Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38.
Article
PubMed
PubMed Central
CAS
Google Scholar
Moon J, Hong J, Jung Y, Ferrannini E, Nauck M, Lim S. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2022;33(6):424–42.
Article
PubMed
CAS
Google Scholar
Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(4):367–78.
Article
PubMed
Google Scholar
Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021. https://doi.org/10.3390/metabo11020073.
Article
PubMed
PubMed Central
CAS
Google Scholar
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90.
Article
PubMed
CAS
Google Scholar
Tang W, Xu Q, Hong T, Tong G, Feng W, Shen S, Bi Y, Zhu D. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev. 2016;32(2):200–16.
Article
PubMed
Google Scholar
Targher G. Tirzepatide adds hepatoprotection to its armoury. Lancet Diabetes Endocrinol. 2022;10(6):374–5.
Article
PubMed
CAS
Google Scholar
Sattar N, McGuire D, Pavo I, Weerakkody G, Nishiyama H, Wiese R, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-Glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites. 2020. https://doi.org/10.3390/metabo11010022.
Article
PubMed
PubMed Central
Google Scholar
Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci. 2020;65(2):623–31.
Article
PubMed
CAS
Google Scholar
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–307.
Article
PubMed
CAS
Google Scholar
Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation. 2017;135(20):1882–93.
Article
PubMed
PubMed Central
CAS
Google Scholar
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz ES, Lovejoy A, et al. Heart Failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. Circulation. 2018;138(12):1210–20.
Article
PubMed
PubMed Central
Google Scholar
Mehtälä J, Khanfir H, Bennett D, Ye Y, Korhonen P, Hoti F. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int. 2019;10(1):24–36.
Article
PubMed
Google Scholar
Portillo-Sanchez P, Bril F, Lomonaco R, Barb D, Orsak B, Bruder J, Cusi K. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial. J Diabetes. 2019;11(3):223–31.
Article
PubMed
CAS
Google Scholar
Zhang X, Ji Y, Cheng X, Cheng Y, Yang H, Wang J, Zhao L, Huang Y, Sun D, Xiang H, et al. A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Sci Transl Med. 2021;13(624):8116.
Article
Google Scholar
Zhang X, She Z, Wang J, Sun D, Shen L, Xiang H, Cheng X, Ji Y, Huang Y, Li P, et al. Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. Sci Transl Med. 2021;13(624):8117.
Article
Google Scholar
Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17(1):40–52.
Article
PubMed
Google Scholar
Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers M. PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease. Gastroenterology. 2017;152(4):912–3.
Article
PubMed
CAS
Google Scholar
Rüschenbaum S, Schwarzkopf K, Friedrich-Rust M, Seeger F, Schoelzel F, Martinez Y, Zeuzem S, Bojunga J, Lange CM. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun. 2018;2(7):798–806.
Article
PubMed
PubMed Central
Google Scholar
Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18(12):809–23.
Article
PubMed
CAS
Google Scholar
Francque S, Szabo G, Abdelmalek M, Byrne C, Cusi K, Dufour J, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol. 2021;18(1):24–39.
Article
PubMed
Google Scholar
Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720–33.
Article
PubMed
CAS
Google Scholar
Francque S, Bedossa P, Ratziu V, Anstee Q, Bugianesi E, Sanyal A, Loomba R, Harrison S, Balabanska R, Mateva L, et al. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385(17):1547–58.
Article
PubMed
CAS
Google Scholar
Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31(7–8):923–30.
Article
PubMed
CAS
Google Scholar
Polyzos SA, Kountouras J, Mantzoros CS, Polymerou V, Katsinelos P. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes Obes Metab. 2017;19(12):1805–9.
Article
PubMed
CAS
Google Scholar
Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol. 2014;20(3):143–53.
Article
PubMed
PubMed Central
Google Scholar
Bril F, Biernacki D, Kalavalapalli S, Lomonaco R, Subbarayan S, Lai J, Tio F, Suman A, Orsak B, Hecht J, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481–8.
Article
PubMed
CAS
Google Scholar
Amanullah I, Khan Y, Anwar I, Gulzar A, Mallhi T, Raja A. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J. 2019;95(1129):601–11.
Article
PubMed
CAS
Google Scholar
Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338–47.
Article
PubMed
Google Scholar
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143.
PubMed
Google Scholar
Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014;20(2):569–77.
Article
PubMed
PubMed Central
Google Scholar
Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916–22.
Article
PubMed
CAS
Google Scholar
Fatima K, Moeed A, Waqar E, Atif A, Kamran A, Rizvi H, Suri N, Haider H, Shuja S, Khalid M, et al. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021;46(4): 101816.
Article
PubMed
Google Scholar
Khoo S, Wong V, Goh G, Fan J, Chan W, Seto W, Chow W. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35(2):320–5.
Article
PubMed
CAS
Google Scholar
Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(6):723–30.
Article
PubMed
PubMed Central
Google Scholar
Theocharidou E, Papademetriou M, Reklou A, Sachinidis A, Boutari C, Giouleme O. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. Curr Pharm Des. 2018;24(31):3654–7.
Article
PubMed
CAS
Google Scholar
Rimbert A, Smati S, Dijk W, Le May C, Cariou B. Genetic inhibition of PCSK9 and liver function. JAMA Cardiol. 2021;6(3):353–4.
Article
PubMed
Google Scholar
Severo M. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(2):523.
Article
PubMed
Google Scholar
Mantovani A, Dalbeni A. Treatments for NAFLD: state of art. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22052350.
Article
PubMed
PubMed Central
CAS
Google Scholar
Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, Yang C, Zong G, Wu J, Jia W. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88–97.
Article
PubMed
Google Scholar
Jeong S, Oh Y, Choi S, Chang J, Kim S, Son J, Lee G, Kim W, Park S. Metabolic dysfunction-associated fatty liver disease better predicts incident cardiovascular disease. Gut and liver. 2021. https://doi.org/10.5009/gnl210256.
Article
PubMed
CAS
Google Scholar
Matsubayashi Y, Fujihara K, Yamada-Harada M, Mitsuma Y, Sato T, Yaguchi Y, Osawa T, Yamamoto M, Kitazawa M, Yamada T, et al. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol. 2022;21(1):90.
Article
PubMed
PubMed Central
Google Scholar